Merck & Co Inc
-
Merck and GE Healthcare Collaborate on Use of Imaging Biomarkers for Investigational BACE inhibitor Clinical Development Program (Tue, Dec 18)
-
Merck Initiates Phase II/III Study of Investigational BACE Inhibitor, MK-8931, for Treatment of Alzheimer's Disease (Mon, Dec 3)
-
Merck Launches Maternal Health Awareness Campaign, Once Upon a Birth, with Actress Melissa Joan Hart (Thu, Nov 29)
-
Merck Provides Update on EU Marketing Authorization Application for Ridaforolimus (Thu, Nov 29)
-
Merck y Endocyte anuncia la aceptación para revisión de las solicitudes de autorización de comercialización europea de vintafolide y del diagnóstico asociado etarfolatide para el tratamiento del cáncer de ovarios... (Wed, Nov 28)
-
Merck Increases Quarterly Dividend (Tue, Nov 27)
-
Merck en Endocyte kondigen acceptatie aan voor evaluatie van Europese handelsvergunningsaanvragen voor vintafolide en voor hulpmiddel voor vergezellende diagnostiek, etarfolatide, voor folaatreceptorpositieve platinaresisten (Tue, Nov 27)
-
Merck und Endocyte melden Prüfungsannahme der europäischen Marktzulassungsanträge für Vintafolide und das Begleitdiagnostikum Etarfolatide zur Behandlung von folatrezeptorpositivem, platinresistenten Eierstockkrebs (Tue, Nov 27)
-
Merck ed Endocyte annunciano l'accettazione della revisione delle richieste di autorizzazione alla commercializzazione nell'Unione europea (UE) per il vintafolide e per l'agente "companion diagnostic" etarfolatide per il car (Tue, Nov 27)
-
Merck et Endocyte annoncent l'acceptation pour examen des dossiers de demande d'autorisation de commercialisation européenne du vintafolide et de l'etarfolatide de diagnostic compagnon pour le traitement du cancer des ovair (Tue, Nov 27)
-
Merck and Endocyte Announce Acceptance for Review of European Marketing Authorization Applications for Vintafolide and Companion Diagnostic Etarfolatide for Folate-Receptor Positive Platinum-Resistant Ovarian Cancer (Tue, Nov 27)
